C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Equipment
SectorN/A
Phone+1-908-2778000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees16,300
OptionableNot Optionable
C R Bard (NYSE:BCR) Frequently Asked Questions
What is C R Bard's stock symbol?
C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."
How were C R Bard's earnings last quarter?
C R Bard Inc (NYSE:BCR) issued its quarterly earnings data on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.06. The medical instruments supplier earned $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. The business's quarterly revenue was up 5.1% compared to the same quarter last year. During the same period last year, the company earned $2.64 earnings per share. View C R Bard's Earnings History.
Has C R Bard been receiving favorable news coverage?
Press coverage about BCR stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. C R Bard earned a media sentiment score of 1.3 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are C R Bard's key executives?
C R Bard's management team includes the folowing people:
- Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)
- John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)
- James C. Beasley, Group President (Age 53)
- Timothy P. Collins, Group President (Age 56)
- John P. Groetelaars, Group President (Age 50)
- Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)
- Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)
- John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)
- Frank Lupisella Jr., Vice President, Controller (Age 56)
- Betty D. Larson, Vice President - Human Resources (Age 41)
How do I buy shares of C R Bard?
Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is C R Bard's official website?
How can I contact C R Bard?
C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000.
MarketBeat Community Rating for C R Bard (NYSE BCR)
MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
